


Sultanate of Oman

Ministry of Health

Directorate General of Pharmaceutical Affairs
and Drug Control

MUSCAT



سُلْطَانَةُ عُمَانُ
رَئَاسَةُ الْعِصَمِيَّةِ
الْمَدْرِيَّةُ الْعَامَّةُ لِلصَّيْرَاتِ
وَالْفَرَاقَاتِ الْدَّرَوِيَّةِ
سَعْدَةٌ

Circular No. 43 / 2019

20 -09-1440 H

26 -05-2019

To:

The Marketing Authorisation Holders / QPPV/ Pharmaceutical Companies

After Compliments,

Sub: Guideline for Direct Healthcare Professional Communications (DHPCs)

This has reference to the Guideline on Good Pharmacovigilance Practices in Oman for MAH and Pharmaceutical companies, Version 1, 2017, (by Circular 5/2017, dated 22/01/2017) and Circular No. 75/2018, dated 27/11/2018, Report to Department of Pharmacovigilance and Drug Information, via MOH e-Portal.

A guideline and a template for the Direct Healthcare Professional Communications (DHPCs) is made available on MOH website for the MAHs and Pharmaceutical companies, to get approval for dissemination of the DHPCs.

You are hereby advised to follow the procedure as laid down by the guideline and adhere to the template as designed for the smooth distribution of the DHPCs.

Yours faithfully,

Ph. Hussain Al Ramimmy
Director, Department of Pharmacovigilance and Drug Information



Cc: DG – for kind inf.